LL-37 Research Bloodwork to Track — What Labs Measure

In published cathelicidin research, the blood-derived measures that recur most often are circulating LL-37/hCAP18 quantified by ELISA, complete blood count with differential (neutrophils carry the precursor protein), acute-phase reactants such as CRP, multiplex cytokine panels, vitamin D status as a correlate of CAMP gene expression, and routine clinical-chemistry panels used as tolerability controls in animal models. Hemolysis and membrane-integrity assays also appear frequently, because LL-37 is a cationic, membrane-active peptide. None of that is monitoring guidance for people. LL-37 and every compound referenced on this page are research use only, and the reason a wholesale buyer should care about any of it is simpler than the biology: assay data is only as interpretable as the material that went into the well.

That last point is the one this article is really about. If you are a med spa owner, clinic operator, telehealth founder, or reseller building a catalog, you are not running the assays — but your customers are, and they will judge your sourcing by whether their numbers make sense. Endotoxin, residual solvent, counterion load, or a purity figure that nobody can verify will all show up as noise in exactly the inflammatory markers researchers are trying to read.

Why cathelicidin shows up in blood work at all

LL-37 is the 37-amino-acid C-terminal fragment of human cathelicidin antimicrobial protein, hCAP18, encoded by the CAMP gene. It is stored as an inactive precursor in the secondary granules of neutrophils and released and cleaved during degranulation, which is why so much of the literature ties LL-37 concentration to leukocyte behavior rather than to a standalone pathway.

Structurally it is cationic and amphipathic, adopting a helical conformation in membrane-like environments. Research suggests it interacts directly with anionic microbial membranes, and studies also report immunomodulatory activity independent of that antimicrobial effect — chemotactic signaling, binding of bacterial lipopolysaccharide, and effects on epithelial and endothelial cell behavior in vitro. Separately, a large body of correlative work associates vitamin D receptor signaling with upregulated CAMP expression, which is why 25-hydroxyvitamin D turns up as a covariate in observational cathelicidin studies.

All of that is compound science, hedged as it should be. It explains why the panels below cluster around immune activity and acute-phase response rather than around a single diagnostic marker.

The marker groups that recur in the literature

Read that table as a map of what buyers will be asked about, not as a protocol. Two things follow from it. First, almost every endpoint in cathelicidin research is an inflammatory or immune readout, and inflammatory readouts are the ones most easily corrupted by contaminated material. Second, the single most common failure mode in peptide research is not a bad hypothesis — it is a vial whose contents were never independently characterized.

Assay noise starts with the vial, not the plate

A researcher measuring IL-6 after exposure to a cationic peptide cannot distinguish, from the readout alone, between peptide activity and a bacterial endotoxin load riding along in the lyophilized powder. That is not a hypothetical concern for antimicrobial peptide work; it is the reason endotoxin and bioburden data exist as separate line items in analytical documentation.

The same applies to purity. A peptide quoted at an unspecified purity, or at a purity nobody outside the supplier can confirm, introduces an unknown fraction of truncated sequences, deletion products, and synthesis byproducts. Those fragments are not inert. For a membrane-active peptide, they can change aggregation behavior and shift dose-response curves in ways that look like real findings.

This is why the documentation conversation matters more than the price conversation when you are building a catalog. A buyer who can hand a customer a batch-specific certificate of analysis and a public purity record is selling something materially different from a buyer who can only forward a supplier's marketing claim.

What to verify before you approve any supplier

Notice what is absent from that table: numbers you are expected to trust. Wholesale terms, minimums, and margins vary widely with volume, compound category, and program structure, and any article that quotes you a specific figure for a supplier it does not operate is guessing. Ask for the numbers directly, in writing, and compare them against documentation quality rather than against each other in isolation.

Compliance questions that belong with your own counsel

This section is informational and is not legal advice. Research-use-only material sits in a regulatory space where the right posture is to ask questions rather than to assume answers, and the questions are more stable than the answers.

Before you stock anything, work through the following with your attorney and, where applicable, your state licensing board: How does your state characterize the sale and possession of research-use-only compounds, and does your business structure change that characterization? What labeling and record-keeping obligations attach to you as a reseller rather than as an end user? Does your professional license, if you hold one, create obligations or restrictions that a non-licensed reseller would not face? What does your insurer require, and does your current policy contemplate this category at all? How do your terms of sale document the research-use-only status of the material to your own customers?

Treat every confident claim you read online about what is or is not permitted as a starting point for that conversation, not a substitute for it. Anyone who tells you the federal or state position on this category is settled is overstating what they know, and a specific statute number quoted without a source is worse than no citation at all. Real Peptides supplies compounds for laboratory research use only, and your own compliance posture remains yours and your counsel's to determine.

What Real Peptides does differently

The wholesale market for research peptides has a documentation problem, and the Real Peptides Wholesale Partner Program is built around removing the parts buyers usually have to take on faith.

Every compound is manufactured to 99%+ HPLC purity. Every batch goes through seven-panel batch testing rather than periodic spot checks on representative lots. Certificates of analysis are publicly verifiable — a partner, or a partner's customer, can check the lab results independently instead of relying on a forwarded PDF or a claim in a product description. That is the practical difference between a supplier that says it tests and a supplier whose testing you can confirm without asking permission.

Fulfillment ships from within the US in 5–7 days, which matters for catalog planning because it removes customs variability from your restock cycle. Onboarding runs through a three-step wholesale application rather than an informal arrangement, so terms are documented before the first order rather than negotiated after a problem. Wholesale pricing is presented as part of that process instead of being held back as leverage.

For buyers whose customers work on inflammation, epithelial, and immune-signaling questions, the catalog depth sits in adjacent categories rather than in any single compound — the KPV Peptide and the broader Gastrointestinal & Epithelial Research collection are the usual starting points, and the same purity and COA standard applies across every SKU.

One clarification worth stating plainly: Real Peptides does not supply semaglutide, tirzepatide, retatrutide, or Melanotan II, and no part of the program should be read as offering them. Supplies are also not bundled with compounds. The catalog is research material, documented as research material.

Where a qualified buyer goes from here

If you are evaluating suppliers for a research-focused catalog and documentation quality is the axis you are judging on, the Wholesale Partner Program application is the next step — three steps, tiered pricing disclosed during onboarding, and COAs you can check before you commit to a single unit. Bring your counsel's read on your own compliance obligations to that conversation; bring the verification questions above to every other supplier you are comparing.

Related reading across the catalog: Popular Peptides, Growth Factor & Tissue Signaling Research, Performance & Recovery Research, Mitochondrial & Metabolic Pathway Research, and Longevity Peptides, alongside individual compounds including BPC-157 10mg, TB-500 10mg, GHK-Cu 50mg, and MOTS-c 10mg.